The clinical success of the application of TNF-α in the setting of isolated limb perfusions in patients with advanced sarcomas, melanomas and other tumors has renewed the interest in TNFa as an anticancer drug in man. We have developed an interactive preclinical-clinical TNFa program that explores new methods to use TNFa in various settings or enhance its activity. Thus we have developed regional organ perfusion models and are testing the effectivity of targeting ofTNF to the tumor by means systemic administration of long circulating liposomes. Furthermore various drugs and mechanisms that may enhance the activity of TNFa are under investigation. An overview of this comprehensive program is presented here.
|Tijdschrift||Journal of Inflammation|
|Nummer van het tijdschrift||1-2|
|Status||Gepubliceerd - 1995|